Ensysce Biosciences to Begin Trading its Common Stock on The Nasdaq Capital Market on July 2, 2021
01 Luglio 2021 - 10:39PM
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ:
ENSC, OTC: ENSCW) today announced that the Company will begin
trading its common stock under the ticker symbol “ENSC” on The
Nasdaq Capital Market and warrants under the ticker symbol “ENSCW”
on the OTC Market on July 2, 2021.
As previously announced, the Company closed its merger with
Leisure Acquisition Corp. (“LACQ”) on June 30, 2021, which was
approved by LACQ’s shareholders on June 28, 2021.
Forward Looking Statements
This press release contains certain forward-looking statements
within the meaning of federal securities laws, including with
respect to the business combination of Ensysce and LACQ.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
communication. Such factors can be found in Ensysce’s most recent
annual report on Form 10-K, subsequently filed quarterly reports on
Form 10-Q and current reports on Form 8-K, which are available,
free of charge, at the SEC’s website at www.sec.gov, and also in
the Form S-4 and Ensysce’s definitive proxy statement/prospectus
relating to the business combination. New risks and uncertainties
arise from time to time, and it is impossible for us to predict
these events or how they may affect the Company. You are cautioned
not to place undue reliance upon any forward-looking statements,
which speak only as of the date made, and Ensysce undertakes no
obligation to update or revise the forward looking statements,
whether as a result of new information, changes in expectations,
future events or otherwise.
About Ensysce Biosciences: Ensysce Biosciences,
San Diego, CA is a clinical-stage biotech company using its
proprietary technology platforms to develop safer prescription
drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP™)
and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is
developing a new class of powerful, tamper-proof opioids that
prevent both drug abuse and overdoses. Ensysce’s products are
anticipated to provide safer options to treat severe pain and
assist in preventing deaths caused by opioid abuse, reducing the
human and economic cost. The platforms are covered by an extensive
worldwide intellectual property portfolio for a wide array of
prescription drug compositions. For more information, please visit
www.ensysce.com.
Investor Relations Contact:Gateway Investor
RelationsMatt Glover, Alex Thompson(949)
574-3860Ensysce@gatewayir.com
Grafico Azioni Leisure Acquisition (NASDAQ:LACQW)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Leisure Acquisition (NASDAQ:LACQW)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Leisure Acquisition Corporation (NASDAQ): 0 articoli recenti
Più Articoli Notizie